{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T15:08:06Z","timestamp":1788188886174,"version":"build-2803163510"},"reference-count":70,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Progress in Cardiovascular Diseases"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1016\/j.pcad.2019.10.003","type":"journal-article","created":{"date-parts":[[2019,10,25]],"date-time":"2019-10-25T11:36:47Z","timestamp":1572003407000},"page":"414-422","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":50,"title":["Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management"],"prefix":"10.1016","volume":"62","author":[{"given":"Marcio H.","family":"Miname","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raul D.","family":"Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pcad.2019.10.003_bb0005","doi-asserted-by":"crossref","DOI":"10.1038\/nrdp.2017.93","article-title":"Familial hypercholesterolaemia","volume":"3","author":"Defesche","year":"2017","journal-title":"Nat Rev Dis Primers"},{"issue":"2","key":"10.1016\/j.pcad.2019.10.003_bb0010","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1194\/jlr.R400012-JLR200","article-title":"Thematic review series: the pathogenesis of atherosclerosis. An interpretive history of the cholesterol controversy: part II: the early evidence linking hypercholesterolemia to coronary disease in humans","volume":"46","author":"Steinberg","year":"2005","journal-title":"J Lipid Res"},{"key":"10.1016\/j.pcad.2019.10.003_bb0015","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/0002-9343(64)90196-2","article-title":"The inheritance of essential familial hypercholesterolemia","volume":"37","author":"Khachadurian","year":"1964","journal-title":"Am J Med"},{"issue":"6","key":"10.1016\/j.pcad.2019.10.003_bb0020","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/j.jacc.2018.05.044","article-title":"Clinical genetic testing for familial hypercholesterolemia: JACC Scientific Expert Panel","volume":"72","author":"Sturm","year":"2018","journal-title":"J Am Coll Cardiol"},{"issue":"9874","key":"10.1016\/j.pcad.2019.10.003_bb0025","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/S0140-6736(12)62127-8","article-title":"Use of low-density lipoprotein cholesterol gene score to distinguish patients with polygenic and monogenic familial hypercholesterolaemia: a case-control study","volume":"381","author":"Talmud","year":"2013","journal-title":"Lancet"},{"issue":"22","key":"10.1016\/j.pcad.2019.10.003_bb0030","doi-asserted-by":"crossref","first-page":"2578","DOI":"10.1016\/j.jacc.2016.03.520","article-title":"Diagnostic yield and clinical utility of sequencing familial hypercholesterolemia genes in patients with severe hypercholesterolemia","volume":"67","author":"Khera","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2019.10.003_bb0035","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.atherosclerosis.2017.05.015","article-title":"Greater preclinical atherosclerosis in treated monogenic familial hypercholesterolemia vs. polygenic hypercholesterolemia","volume":"263","author":"Sharifi","year":"2017","journal-title":"Atherosclerosis"},{"issue":"4","key":"10.1016\/j.pcad.2019.10.003_bb0040","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.jacc.2019.05.043","article-title":"Risk of premature atherosclerotic disease in patients with monogenic versus polygenic familial hypercholesterolemia","volume":"74","author":"Trinder","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"45","key":"10.1016\/j.pcad.2019.10.003_bb0045","doi-asserted-by":"crossref","first-page":"3478","DOI":"10.1093\/eurheartj\/eht273","article-title":"Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society","volume":"34","author":"Nordestgaard","year":"2013","journal-title":"Eur Heart J"},{"issue":"2","key":"10.1016\/j.pcad.2019.10.003_bb0050","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.jacl.2019.01.009","article-title":"Comparative aspects of the care of familial hypercholesterolemia in the \u201cTen Countries Study\u201d","volume":"13","author":"Pang","year":"2019","journal-title":"J Clin Lipidol"},{"issue":"21","key":"10.1016\/j.pcad.2019.10.003_bb0055","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1161\/CIRCULATIONAHA.117.032321","article-title":"Predictors of cholesterol screening, awareness, and statin treatment among US adults with familial hypercholesterolemia or other forms of severe dyslipidemia (1999-2014)","volume":"137","author":"Bucholz","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.pcad.2019.10.003_bb0060","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.atherosclerosis.2018.04.040","article-title":"Coronary heart disease mortality in treated familial hypercholesterolaemia: update of the UK Simon Broome FH register","volume":"274","author":"Humphries","year":"2018","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.pcad.2019.10.003_bb2005","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1161\/CIRCULATIONAHA.118.033470","article-title":"Relationship of familial hypercholesterolemia and high low-density lipoprotein cholesterol to ischemic stroke","volume":"138","author":"Beheshti","year":"2018","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.pcad.2019.10.003_bb0065","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1177\/2047487316676135","article-title":"Cardiovascular disease mortality in patients with genetically verified familial hypercholesterolemia in Norway during 1992-2013","volume":"24","author":"Mundal","year":"2017","journal-title":"Eur J Prev Cardiol"},{"issue":"9","key":"10.1016\/j.pcad.2019.10.003_bb0070","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1161\/ATVBAHA.116.307514","article-title":"Coronary heart disease, peripheral arterial disease, and stroke in familial hypercholesterolaemia: insights from the SAFEHEART Registry (Spanish Familial Hypercholesterolaemia Cohort Study)","volume":"36","author":"Perez de Isla","year":"2016","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"1","key":"10.1016\/j.pcad.2019.10.003_bb0075","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.atherosclerosis.2015.07.022","article-title":"Peripheral arterial disease in heterozygous familial hypercholesterolemia","volume":"242","author":"Pereira","year":"2015","journal-title":"Atherosclerosis"},{"issue":"10","key":"10.1016\/j.pcad.2019.10.003_bb0080","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/S2213-8587(16)30041-9","article-title":"Defining severe familial hypercholesterolaemia and the implications for clinical management: a consensus statement from the International Atherosclerosis Society Severe Familial Hypercholesterolemia Panel","volume":"4","author":"Santos","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"6","key":"10.1016\/j.pcad.2019.10.003_bb0085","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1111\/j.1365-2796.2004.01405.x","article-title":"The contribution of classical risk factors to cardiovascular disease in familial hypercholesterolaemia: data in 2400 patients","volume":"256","author":"Jansen","year":"2004","journal-title":"J Intern Med"},{"issue":"1","key":"10.1016\/j.pcad.2019.10.003_bb0090","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.jacl.2018.10.012","article-title":"Risk factors for cardiovascular disease in heterozygous familial hypercholesterolemia: a systematic review and meta-analysis","volume":"13","author":"Akioyamen","year":"2019","journal-title":"J Clin Lipidol"},{"issue":"4","key":"10.1016\/j.pcad.2019.10.003_bb0095","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1111\/j.1365-2362.2005.01484.x","article-title":"Pathogenesis, detection and treatment of Achilles tendon xanthomas","volume":"35","author":"Tsouli","year":"2005","journal-title":"Eur J Clin Invest"},{"issue":"1","key":"10.1016\/j.pcad.2019.10.003_bb0100","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.atherosclerosis.2014.11.009","article-title":"Familial hypercholesterolemia in Brazil: cascade screening program, clinical and genetic aspects","volume":"238","author":"Jannes","year":"2015","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.pcad.2019.10.003_bb0105","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.atherosclerosis.2017.04.025","article-title":"Achilles tendon xanthomas are associated with the presence and burden of subclinical coronary atherosclerosis in heterozygous familial hypercholesterolemia: a pilot study","volume":"263","author":"Mangili","year":"2017","journal-title":"Atherosclerosis"},{"issue":"suppl 3","key":"10.1016\/j.pcad.2019.10.003_bb0110","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.1016\/j.jacl.2011.03.451","article-title":"Treatment of adults with familial hypercholesterolemia and evidence for treatment: recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia","volume":"5","author":"Robinson","year":"2011","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.pcad.2019.10.003_bb0115","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.atherosclerosis.2017.06.009","article-title":"Effect of intensive LDL cholesterol lowering with PCSK9 monoclonal antibodies on tendon xanthoma regression in familial hypercholesterolemia","volume":"263","author":"Bea","year":"2017","journal-title":"Atherosclerosis"},{"issue":"20","key":"10.1016\/j.pcad.2019.10.003_bb0120","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1093\/eurheartj\/ehx033","article-title":"Lipoprotein(a): the revenant","volume":"38","author":"Gencer","year":"2017","journal-title":"Eur Heart J"},{"issue":"2","key":"10.1016\/j.pcad.2019.10.003_bb0125","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1161\/CIRCULATIONAHA.107.715698","article-title":"Extreme lipoprotein(a) levels and risk of myocardial infarction in the general population: the Copenhagen City Heart Study","volume":"117","author":"Kamstrup","year":"2008","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.pcad.2019.10.003_bb0130","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.jacc.2013.09.038","article-title":"Elevated lipoprotein(a) and risk of aortic valve stenosis in the general population","volume":"63","author":"Kamstrup","year":"2014","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"10.1016\/j.pcad.2019.10.003_bb0135","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1001\/jama.2009.1063","article-title":"Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality","volume":"302","author":"Emerging Risk Factors","year":"2009","journal-title":"Jama"},{"issue":"19","key":"10.1016\/j.pcad.2019.10.003_bb0140","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1016\/j.jacc.2014.01.063","article-title":"Lipoprotein(a) levels in familial hypercholesterolemia: an important predictor of cardiovascular disease independent of the type of LDL receptor mutation","volume":"63","author":"Alonso","year":"2014","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.pcad.2019.10.003_bb0145","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.jacl.2016.10.004","article-title":"The Montreal-FH-SCORE: a new score to predict cardiovascular events in familial hypercholesterolemia","volume":"11","author":"Paquette","year":"2017","journal-title":"J Clin Lipidol"},{"issue":"22","key":"10.1016\/j.pcad.2019.10.003_bb0150","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1161\/CIRCULATIONAHA.116.024541","article-title":"Predicting cardiovascular events in familial hypercholesterolemia: the SAFEHEART Registry (Spanish Familial Hypercholesterolemia Cohort Study)","volume":"135","author":"Perez de Isla","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.pcad.2019.10.003_bb0155","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.atherosclerosis.2019.05.003","article-title":"Potential utility of the SAFEHEART risk equation for rationalising the use of PCSK9 monoclonal antibodies in adults with heterozygous familial hypercholesterolemia","volume":"286","author":"Perez de Isla","year":"2019","journal-title":"Atherosclerosis"},{"issue":"25","key":"10.1016\/j.pcad.2019.10.003_bb0160","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1093\/eurheartj\/ehy217","article-title":"Ten-year association of coronary artery calcium with atherosclerotic cardiovascular disease (ASCVD) events: the multi-ethnic study of atherosclerosis (MESA)","volume":"39","author":"Budoff","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pcad.2019.10.003_bb0165","article-title":"Long-term all-cause and cause-specific mortality in asymptomatic patients with CAC >\/=1,000: results from the CAC consortium","author":"Peng","year":"2019","journal-title":"JACC Cardiovasc Imaging"},{"issue":"24","key":"10.1016\/j.pcad.2019.10.003_bb0170","doi-asserted-by":"crossref","first-page":"e285","DOI":"10.1016\/j.jacc.2018.11.003","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"73","author":"Grundy","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.pcad.2019.10.003_bb0175","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.atherosclerosis.2007.12.014","article-title":"No correlation and low agreement of imaging and inflammatory atherosclerosis' markers in familial hypercholesterolemia","volume":"200","author":"Martinez","year":"2008","journal-title":"Atherosclerosis"},{"issue":"2","key":"10.1016\/j.pcad.2019.10.003_bb0180","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.atherosclerosis.2010.10.001","article-title":"Evaluation of subclinical atherosclerosis by computed tomography coronary angiography and its association with risk factors in familial hypercholesterolemia","volume":"213","author":"Miname","year":"2010","journal-title":"Atherosclerosis"},{"issue":"2","key":"10.1016\/j.pcad.2019.10.003_bb0185","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/j.atherosclerosis.2011.09.052","article-title":"Accelerated subclinical coronary atherosclerosis in patients with familial hypercholesterolemia","volume":"219","author":"Neefjes","year":"2011","journal-title":"Atherosclerosis"},{"issue":"3","key":"10.1016\/j.pcad.2019.10.003_bb0190","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/j.jacl.2017.03.016","article-title":"Early coronary calcifications are related to cholesterol burden in heterozygous familial hypercholesterolemia","volume":"11","author":"Gallo","year":"2017","journal-title":"J Clin Lipidol"},{"issue":"9","key":"10.1016\/j.pcad.2019.10.003_bb0195","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1016\/j.jcmg.2018.09.019","article-title":"Coronary artery calcium and cardiovascular events in patients with familial hypercholesterolemia receiving standard lipid-lowering therapy","volume":"12","author":"Miname","year":"2019","journal-title":"JACC Cardiovasc Imaging"},{"issue":"4","key":"10.1016\/j.pcad.2019.10.003_bb0200","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1016\/j.jacl.2018.04.003","article-title":"Coronary computed tomographic angiography findings and their therapeutic implications in asymptomatic patients with familial hypercholesterolemia. Lessons from the SAFEHEART study","volume":"12","author":"Perez de Isla","year":"2018","journal-title":"J Clin Lipidol"},{"issue":"5","key":"10.1016\/j.pcad.2019.10.003_bb0205","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s12410-017-9412-6","article-title":"The updated NICE guidelines: cardiac CT as the first-line test for coronary artery disease","volume":"10","author":"Moss","year":"2017","journal-title":"Curr Cardiovasc Imaging Rep"},{"issue":"14","key":"10.1016\/j.pcad.2019.10.003_bb0210","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1136\/hrt.2010.220699","article-title":"CT coronary plaque burden in asymptomatic patients with familial hypercholesterolaemia","volume":"97","author":"Neefjes","year":"2011","journal-title":"Heart"},{"issue":"6","key":"10.1016\/j.pcad.2019.10.003_bb0215","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.amjcard.2014.12.034","article-title":"Assessment of coronary atherosclerosis in patients with familial hypercholesterolemia by coronary computed tomography angiography","volume":"115","author":"Tada","year":"2015","journal-title":"Am J Cardiol"},{"issue":"9406","key":"10.1016\/j.pcad.2019.10.003_bb0220","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/S0140-6736(04)15467-6","article-title":"Arterial intima-media thickness in children heterozygous for familial hypercholesterolaemia","volume":"363","author":"Wiegman","year":"2004","journal-title":"Lancet"},{"issue":"9256","key":"10.1016\/j.pcad.2019.10.003_bb0225","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/S0140-6736(00)04053-8","article-title":"Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double-blind trial","volume":"357","author":"Smilde","year":"2001","journal-title":"Lancet"},{"issue":"14","key":"10.1016\/j.pcad.2019.10.003_bb0230","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1056\/NEJMoa0800742","article-title":"Simvastatin with or without ezetimibe in familial hypercholesterolemia","volume":"358","author":"Kastelein","year":"2008","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.pcad.2019.10.003_bb0235","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1001\/jama.2012.9624","article-title":"Comparison of novel risk markers for improvement in cardiovascular risk assessment in intermediate-risk individuals","volume":"308","author":"Yeboah","year":"2012","journal-title":"Jama"},{"key":"10.1016\/j.pcad.2019.10.003_bb0240","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.atherosclerosis.2018.11.014","article-title":"Coronary heart disease mortality in severe vs. non-severe familial hypercholesterolaemia in the Simon Broome Register","volume":"281","author":"Humphries","year":"2019","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.pcad.2019.10.003_bb0245","first-page":"337","article-title":"Efficacy of statins in familial hypercholesterolaemia: a long term cohort study","volume":"a2423","author":"Versmissen","year":"2008","journal-title":"BMJ (Clin Res Ed)"},{"issue":"3","key":"10.1016\/j.pcad.2019.10.003_bb0250","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.jacc.2016.04.054","article-title":"Statins in familial hypercholesterolemia: consequences for coronary artery disease and all-cause mortality","volume":"68","author":"Besseling","year":"2016","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"10.1016\/j.pcad.2019.10.003_bb0255","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/j.jacl.2018.03.088","article-title":"Cardiovascular event reduction with PCSK9 inhibition among 1578 patients with familial hypercholesterolemia: results from the SPIRE randomized trials of bococizumab","volume":"12","author":"Ridker","year":"2018","journal-title":"J Clin Lipidol"},{"issue":"11","key":"10.1016\/j.pcad.2019.10.003_bb0260","doi-asserted-by":"crossref","first-page":"3956","DOI":"10.1210\/jc.2012-1563","article-title":"Familial hypercholesterolemia in the danish general population: prevalence, coronary artery disease, and cholesterol-lowering medication","volume":"97","author":"Benn","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"10.1016\/j.pcad.2019.10.003_bb0265","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1517\/14656566.2015.1041504","article-title":"Ezetimibe plus simvastatin for the treatment of hypercholesterolemia","volume":"16","author":"Gryn","year":"2015","journal-title":"Expert Opin Pharmacother"},{"issue":"25","key":"10.1016\/j.pcad.2019.10.003_bb0270","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe added to statin therapy after acute coronary syndromes","volume":"372","author":"Cannon","year":"2015","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.pcad.2019.10.003_bb0275","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/ng1161","article-title":"Mutations in PCSK9 cause autosomal dominant hypercholesterolemia","volume":"34","author":"Abifadel","year":"2003","journal-title":"Nat Genet"},{"key":"10.1016\/j.pcad.2019.10.003_bb0280","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1146\/annurev-pharmtox-010716-104944","article-title":"PCSK9: regulation and target for drug development for dyslipidemia","volume":"57","author":"Burke","year":"2017","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"3","key":"10.1016\/j.pcad.2019.10.003_bb0285","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/s41569-018-0107-8","article-title":"PCSK9 inhibitors: clinical evidence and implementation","volume":"16","author":"Sabatine","year":"2019","journal-title":"Nat Rev Cardiol"},{"issue":"18","key":"10.1016\/j.pcad.2019.10.003_bb0290","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.pcad.2019.10.003_bb0295","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and cardiovascular outcomes after acute coronary syndrome","volume":"379","author":"Schwartz","year":"2018","journal-title":"N Engl J Med"},{"issue":"31","key":"10.1016\/j.pcad.2019.10.003_bb0300","doi-asserted-by":"crossref","first-page":"3647","DOI":"10.2174\/1381612824666181010124657","article-title":"Role of PCSK9 inhibitors in high risk patients with dyslipidemia: focus on familial hypercholesterolemia","volume":"24","author":"Papademetriou","year":"2018","journal-title":"Curr Pharm Des"},{"issue":"14","key":"10.1016\/j.pcad.2019.10.003_bb0305","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1093\/eurheartj\/ehx549","article-title":"2017 update of ESC\/EAS Task Force on practical clinical guidance for proprotein convertase subtilisin\/kexin type 9 inhibition in patients with atherosclerotic cardiovascular disease or in familial hypercholesterolaemia","volume":"39","author":"Landmesser","year":"2018","journal-title":"Eur Heart J"},{"issue":"31","key":"10.1016\/j.pcad.2019.10.003_bb0310","doi-asserted-by":"crossref","first-page":"3634","DOI":"10.2174\/1381612824666181025115658","article-title":"Lipoprotein apheresis and PCSK9-inhibitors. Impact on atherogenic lipoproteins and anti-inflammatory mediators in familial hypercholesterolaemia","volume":"24","author":"Stefanutti","year":"2018","journal-title":"Curr Pharm Des"},{"issue":"17","key":"10.1016\/j.pcad.2019.10.003_bb0315","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1056\/NEJMoa1602777","article-title":"Child-parent familial hypercholesterolemia screening in primary care","volume":"375","author":"Wald","year":"2016","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.pcad.2019.10.003_bb0320","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.jacl.2014.05.008","article-title":"Cascade screening based on genetic testing is cost-effective: evidence for the implementation of models of care for familial hypercholesterolemia","volume":"8","author":"Ademi","year":"2014","journal-title":"J Clin Lipidol"},{"issue":"4","key":"10.1016\/j.pcad.2019.10.003_bb0325","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.jacl.2019.05.004","article-title":"Low-density lipoprotein cholesterol goal achievement in patients with familial hypercholesterolemia in countries outside western Europe: the International ChoLesterol management Practice Study","volume":"13","author":"Blom","year":"2019","journal-title":"J Clin Lipidol"},{"issue":"11","key":"10.1016\/j.pcad.2019.10.003_bb0330","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/j.jacc.2016.01.008","article-title":"Attainment of LDL-cholesterol treatment goals in patients with familial hypercholesterolemia: 5-year SAFEHEART registry follow-up","volume":"67","author":"Perez de Isla","year":"2016","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"10.1016\/j.pcad.2019.10.003_bb0335","doi-asserted-by":"crossref","first-page":"e005404","DOI":"10.1161\/CIRCOUTCOMES.118.005404","article-title":"Effect of access to prescribed PCSK9 inhibitors on cardiovascular outcomes","volume":"12","author":"Myers","year":"2019","journal-title":"Circulation Cardiovascular Quality and Outcomes"},{"issue":"1","key":"10.1016\/j.pcad.2019.10.003_bb0340","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1161\/01.ATV.16.1.129","article-title":"Lp(a) levels and atherosclerotic vascular disease in a sample of patients with familial hypercholesterolemia sharing the same gene defect","volume":"16","author":"Carmena","year":"1996","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"4","key":"10.1016\/j.pcad.2019.10.003_bb0345","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/j.jacl.2019.04.006","article-title":"LPA genotype is associated with premature cardiovascular disease in familial hypercholesterolemia","volume":"13","author":"Paquette","year":"2019","journal-title":"J Clin Lipidol"}],"container-title":["Progress in Cardiovascular Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0033062019301288?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0033062019301288?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T00:16:12Z","timestamp":1758500172000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0033062019301288"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":70,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["S0033062019301288"],"URL":"https:\/\/doi.org\/10.1016\/j.pcad.2019.10.003","relation":{},"ISSN":["0033-0620"],"issn-type":[{"value":"0033-0620","type":"print"}],"subject":[],"published":{"date-parts":[[2019,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management","name":"articletitle","label":"Article Title"},{"value":"Progress in Cardiovascular Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pcad.2019.10.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}